Eurocine Vaccines is publically listed at Spotlight Stock Market XSAT, Sweden, with the ticker EUCI.
To be notified with news, sign up to our newsfeed =>
Legal Advisor is Lindahl and MCL.
Sedermera is our Financial Advisor.
Patent and Intellectual Property (IP) advisors are Zacco and AWA.
.
Preferential Share Issue
Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of shares up to cirka 9,7 MSEK before issue costs, which subscription period begins Wednesday 2 August 2023.
Eurocine Vaccines´ Memorandum 2023 (in Swedish)
Supplementary Memorandum 7 August 2023 (Tilläggsmemorandum, in Swedish)
Extraordinary General Meeting
26 July 2023
Below follow documents related to the Extraordinary General Meeting on the 26 July 2023:
Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)
Proxy Form (Fullmaktsformulär, in Swedish)
Latest Investor Presentation
Future Financial Reports
The Interim Report July – December 2023 is planned to be available 28 February 2024.
Existing Financial Reports
Interim Report July – September 2023
Annual Report 2022 – 2023 (Swedish)
Full Year Report July 2022 – June 2023
Interim Report July 2022 – March 2023
Interim Report July – December 2022
Interim Report July – September 2022
Full Year Report July 2021 – June 2022 =>
Interim Report July 2021 – March 2022 =>
Interim Report July – December 2021 =>
Interim Report July – September 2021 =>
Full Year Report July 2020 – June 2021 =>
Interim Report July 2020 – March 2021 =>